ABSTRACT
Conclusion:
In this study, we found no significant difference in terms of efficacy and safety between the outpatient and the inpatient based mobilization group patients with myeloma and lymphoma who were mobilized with G-CSF. The results of our study show that outpatient based mobilization can be effectively and safely performed with g-csf, especially in patients who need autologous transplantation and avoid hospitalization, as in the current Coronavirus disease-2019 pandemic.
Results:
Three leukaphereses resulted in the collection of a mean 9.73x106/kg (4.5-16.5) CD34+ cells in the outpatient based mobilization group and a mean 11.8x106/kg (3.56-59) CD34+ cells in the inpatient based mobilization group (p=0.14). Life-threatening side effects were not observed in any of the patients. Grade 1, 2 side effects were observed and there was no significant statistical difference between the two groups.
Materials and Methods:
A total of 89 patients, including 54 patients who underwent outpatient and 35 patients who underwent inpatient based mobilization of stem cells with G-CSF alone were included in the study. Outpatient and inpatient based mobilization groups were compared in terms of efficacy and safety. Statistical analyses were performed with Jamovi 1.2.27 software. The Mann-Whitney U and chi-square tests were used to examine the differences. MANCOVA was used for univariate and multivariate statistical analysis of factors influencing mobilization.
Aim:
Autologous hematopoietic stem cell transplantation is the most frequently used treatment method in the treatment of lymphoma and myeloma patients. To apply this treatment method, first of all, a sufficient number of stem cells must be collected from the patient. With the development of apheresis methods and safe, effective mobilization methods, it is now possible to collect stem cells in an outpatient manner. In our study, we aimed to compare the efficacy and safety of outpatient based mobilization versus inpatient based mobilization of hematopoietic stem cells with granulocyte-colony stimulating factor (G-CSF) alone in patients with myeloma and lymphoma.
INTRODUCTION
High-dose chemotherapy with autologous hematopoietic stem cell transplantation is frequently used in the treatment of patients with multiple myeloma (MM), non-Hodgkin’s lymphoma (NHL), and Hodgkin’s lymphoma (HL)1-3. The first requirement for this treatment is the collection of a sufficient number of hematopoietic stem cells (HSCs). HSCs can be collected in two ways. Historically, HSCs were collected via multiple bone marrow aspirations from bilateral iliac crests. This method is used for limited indications today. The other way is the collection by leukapheresis after mobilization of HSCs into the peripheral blood. With the development of apheresis methods and safe, effective mobilization methods towards the end of the 20th century, it is now possible to collect stem cells in an outpatient manner. Moreover, today, the Coronavirus disease-2019 (COVID-19) pandemic has made it clear that home remedies are necessary and may be needed in the future. In the setting of the COVID-19 pandemic, many patients avoid hospitalization. Therefore, outpatient based mobilization has become even more important.
In this retrospective study, we aimed to evaluate the effectiveness and safety of the HSC mobilization with granulocyte-colony stimulating factor (G-CSF) which was performed in the inpatient setting and in the outpatient setting for the patients who had hematological malignancies (MM, NHL, HL).
MATERIALS AND METHODS
Demographic and Baseline Characteristics
A total of 89 patients, including 54 patients who underwent HSCs outpatient based mobilization and 35 patients who underwent inpatient based mobilization with G-CSF alone, between 2012 and 2019, were included in the study. Our study objective was to evaluate the efficacy and safety of the HSC mobilization with G-CSF which was performed in the inpatient setting and in the outpatient setting for the patients who had hematological malignancies (MM, NHL, HL). In the outpatient based mobilization group, there were 39 patients with myeloma, 14 patients with NHL, (nine patients with diffuse large b-cell lymphoma (DLBCL), two patients with mantle cell lymphoma (MCL), two patients with follicular lymphoma, and one patient with MALT lymphoma), and one patient with HL.
The inpatient mobilization group included 24 patients with myeloma, five patients with NHL (two DLBCL, one MCL, one peripheral t-cell lymphoma, one Burkitt lymphoma), and six patients with HL.
The demographic and baseline characteristics, previous chemotherapy lines, HSC collection data of the patients are summarized in Table 1.
MM and lymphoma patients aged 18-75 years, mobilized only with G-CSF, were included in the study.
G-CSF (filgrastim) at a dose of 5 mcg/kg twice a day subcutaneously was administered as a mobilizing agent in all patients. Monitoring of peripheral blood CD34+ cells began on the fourth day of G-CSF administration and was performed daily. Leukapheresis was initiated if the CD34+ cell count had reached >10/μL in the peripheral blood.
Before harvesting, all lymphoma patients had complete remission and their bone marrow was normocellular without lymphoma infiltration. Patients with myeloma also had a complete response or very good partial response. None of them had received immunomodulatory drugs (imid) treatment prior to mobilization. The peripheral stem cell harvesting was performed with an Amicus Fenwal apheresis device and calcium infused to prevent citrate-related complications. Venous access was provided via a central venous catheter in all patients. Age, sex, body weight, diagnosis, time to stem cell collection, total mononuclear cell count, and CD34+ cell count at the beginning of the collection, time to reach the target CD34+ cell count, product CD34+ cell counts, adverse reactions and complications were recorded.
All patients gave written informed consent. Our study was approved by the Ethics Committee of Necmettin Erbakan University Medicine Faculty with the 2019/2079 consent number.
Statistical Analysis
Statistical analyses were performed with Jamovi 1.2.27 software. The Mann-Whitney U test was used to examine the differences. A chi-square test was used to compare sex values between the groups. MANCOVA was used for univariate and multivariate statistical analysis of factors influencing mobilization. A p value of <0.05 was considered statistically significant.
Efficacy Outcomes
Minimal and target stem cell counts were considered ≥2x106 CD34+ cells/kg and ≥4x106 CD34+ cells/kg for lymphoma patients and ≥4x106 CD34+ cells/kg and ≥6x106 CD34+ cells/kg for myeloma patients.
The inability to achieve minimal CD34+ cell counts after 3 courses of apheresis was defined as “mobilization failure”.
RESULTS
Two patients, who failed a first mobilization attempt using G-CSF in the outpatient based mobilization group, were identified. Three patients had mobilization failure in the inpatient based mobilization group. So, in a total of 84 patients, including 52 patients who underwent outpatient based mobilization and 32 patients who underwent inpatient based mobilization, HSCs were collected successfully.
The effect of baseline status on the mobilization of CD34+ cells is shown in Table 2.
The target CD34+ cell count was achieved in one leukapheresis procedure in 15 patients, two procedures in 34 patients, and three procedures in three patients who performed outpatient based mobilization. For the patients who were inpatient based mobilized of HSCs, the target CD34+ cell count was reached in one procedure in nine patients, in two procedures in 18 patients, and three procedures in five patients. There was no significant difference between the groups (p=0.39).
Total processed blood volume was 10,530+1,180 mL in the outpatient based mobilization group and 11220+1180 mL in the inpatient based mobilization group, and there was no statistically significant difference between the groups. Three leukaphereses resulted in the collection of a mean 9.73 (4.5-16.5)x106/kg CD34+cells in the outpatient based mobilization group and a mean 11.8 (3.56-59)x106/kg CD34+ cells in the inpatient based mobilization group (p=0.14) (Table 3).
Statistical analysis of factors influencing mobilization is presented in Table 4 and Figure 1.
Life-threatening side effects were not observed in any of the patients. Common terminology criteria for adverse events (CTCAE) Grade 1,2 side effects, including nausea, bone pain, fatigue, and fever, were observed and there was no statistically significant difference between the two groups.
DISCUSSION
HSC mobilization for autologous transplantation can be performed using chemotherapy plus G-CSF or G-CSF alone4. Stem cell mobilization with chemotherapy + G-CSF is usually performed in the inpatient group. In our country, too, G-CSF alone or chemotherapy + G-CSF is used as the first mobilization protocol. Although less than stem cell mobilization with chemotherapy + G-CSF, side effects are also seen in stem cell mobilization with G-CSF alone. Bone pain, chest pain, fatigue, back pain, fever, nausea, splenomegaly, and skin rash are relatively common adverse reactions of G-CSF. Rarely, life-threatening complications such as splenic rupture, stroke, myocardial infarction, anaphylaxis, aortitis, and capillary leak syndrome can occur, especially when used in high doses of G-CSF5-7.
Spontaneous splenic rupture following the administration of G-CSF occurred very rarely both in autologous and allogeneic donors of peripheral stem cells. There are few case reports on this issue in the medical literature5-8. Inpatient based stem cell mobilization may be advantageous in terms of closely monitoring these side effects. However, life-threatening side effects are extremely rare. Patients should be informed about life-threatening side effects and their transportation facilities should be reviewed.
In the case report of Nuamah et al.7 about spontaneous splenic rupture and review of the literature, a healthy female allogeneic peripheral stem cell donor, who was given 20 mcg/day G-CSF, developed a splenic rupture presenting with sudden sharp left upper quadrant pain, and emergent splenectomy was performed. In this publication, Nuamah et al.7 recommended close monitoring of patients, informing patients and donors about potential fatal complications, and avoiding vigorous activities because of the possibility of damage to the fragile spleen even from minor traumas. Similarly, in six cases of spontaneous splenic rupture, previously published by Falzetti et al.9, Dincer et al.10, Balaguer et al.11, Kasper et al.12, O`Malley et al.13, and Pitini et al.14, the dose of G-CSF used in these cases was between 5 and 20 mcg/day. In the literature, most reported cases of splenic rupture had occurred within the days of apheresis and beyond. A definite correlation could not be established with the dose of G-CSF.
Study Limitations
In our study, CTCAE Grade 1, 2 mild side effects were observed in both inpatient and outpatient mobilization patients (nausea, bone pain, fatigue, and fever). None of the rare life-threatening side effects were observed in our study.
Nevertheless, the fact that it is not a prospective study and the relatively small number of patients are the limitations of our study. It was revealed from this study that there was no difference between the two groups, but this is not enough to say that there is no difference in terms of security as a whole.
CONCLUSION
In this study, we found no significant difference in terms of efficacy and safety between the outpatient based mobilization group and the inpatient based mobilization group in patients with MM and lymphoma, who were mobilized with G-CSF. The results of our study show that outpatient based mobilization can be performed with G-CSF, especially in patients who need autologous transplantation and avoid hospitalization, as in the current COVID-19 pandemic. However, although extremely rare, patients should be informed about possible fatal complications and rapid access to the hospital should be evaluated individually. Prospective, randomized studies are needed for clearer data on this subject.
